

Alberto Espay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4018451/publications.pdf>

Version: 2024-02-01

378
papers

14,831
citations

16450

64
h-index

30081

103
g-index

393
all docs

393
docs citations

393
times ranked

13065
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology, The</i> , 2014, 13, 141-149.	10.2	547
2	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	3.9	464
3	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018, 75, 1132.	9.0	455
4	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	7.6	286
5	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	3.9	275
6	A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. <i>Nature Genetics</i> , 2015, 47, 39-46.	21.4	245
7	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	3.9	244
8	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	5.3	225
9	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019, 34, 657-663.	3.9	213
10	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 141.	9.0	211
11	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	3.9	199
12	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	5.3	195
13	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.1	194
14	Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement. <i>Movement Disorders</i> , 2014, 29, 1710-1719.	3.9	190
15	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. <i>Lancet Neurology, The</i> , 2013, 12, 346-356.	10.2	182
16	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology, The</i> , 2020, 19, 462-470.	10.2	181
17	On-state freezing of gait in Parkinson disease. <i>Neurology</i> , 2012, 78, 454-457.	1.1	178
18	<i>APOE</i> , <i>MAPT</i> , and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	9.0	172

#	ARTICLE	IF	CITATIONS
19	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	3.9	158
20	The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures. <i>Movement Disorders</i> , 2011, 26, 1859-1863.	3.9	152
21	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017, 32, 319-324.	3.9	145
22	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 119-126.	10.1	141
23	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009, 24, 1366-1374.	3.9	138
24	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	5.3	133
25	Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2504-2508.	3.9	126
26	Clinician versus machine: Reliability and responsiveness of motor endpoints in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 590-595.	2.2	125
27	At-home training with closed-loop augmented-reality cueing device for improving gait in patients with Parkinson disease. <i>Journal of Rehabilitation Research and Development</i> , 2010, 47, 573.	1.6	118
28	Rigidity and spasms from autoimmune encephalomyelopathies: Stiff-person syndrome. <i>Muscle and Nerve</i> , 2006, 34, 677-690.	2.2	113
29	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.1	112
30	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	2.5	110
31	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	4.2	108
32	Autonomic dysfunction in Parkinson's disease: A prospective cohort study. <i>Movement Disorders</i> , 2018, 33, 391-397.	3.9	108
33	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	3.9	104
34	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , The, 2020, 19, 452-461.	10.2	104
35	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.1	103
36	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	10.2	100

#	ARTICLE	IF	CITATIONS
37	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 692-697.	2.2	99
38	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. <i>Movement Disorders</i> , 2007, 22, 813-821.	3.9	97
39	Mirror movements in parkinsonism: evaluation of a new clinical sign. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1355-1359.	1.9	96
40	Feasibility of home-based automated Parkinson's disease motor assessment. <i>Journal of Neuroscience Methods</i> , 2012, 203, 152-156.	2.5	95
41	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 339-345.	2.2	95
42	Telemedicine in Neurological Disorders: Opportunities and Challenges. <i>Telemedicine Journal and E-Health</i> , 2019, 25, 541-550.	2.8	94
43	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	10.2	94
44	Psychogenic facial movement disorders: Clinical features and associated conditions. <i>Movement Disorders</i> , 2012, 27, 1544-1551.	3.9	93
45	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015, 10, 50.	10.8	91
46	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	3.9	91
47	Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders. <i>JAMA Neurology</i> , 2021, 78, 88.	9.0	90
48	Tics and functional tic-like movements. <i>Neurology</i> , 2019, 93, 750-758.	1.1	89
49	Vascular Parkinsonism: Deconstructing a Syndrome. <i>Movement Disorders</i> , 2015, 30, 886-894.	3.9	88
50	Methylphenidate for gait impairment in Parkinson disease. <i>Neurology</i> , 2011, 76, 1256-1262.	1.1	86
51	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	10.2	80
52	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 926.	7.4	80
53	Mutations in ZBTB20 cause Primrose syndrome. <i>Nature Genetics</i> , 2014, 46, 815-817.	21.4	79
54	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018, 33, 21-35.	3.9	79

#	ARTICLE	IF	CITATIONS
55	Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda. <i>NeuroImage: Clinical</i> , 2021, 30, 102623.	2.7	79
56	Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: Preliminary observations. <i>Movement Disorders</i> , 2008, 23, 2357-2362.	3.9	78
57	Movement Disorders on YouTube â€” Caveat Spectator. <i>New England Journal of Medicine</i> , 2011, 365, 1160-1161.	27.0	77
58	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 638-649.	1.9	77
59	Psychiatric associations of adult-onset focal dystonia phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 595-602.	1.9	76
60	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 566-571.	1.9	76
61	â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1311-1321.	1.9	75
62	Essential pitfalls in â€œessentialâ€™ tremor. <i>Movement Disorders</i> , 2017, 32, 325-331.	3.9	74
63	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019, 93, e1787-e1798.	1.1	73
64	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in Î±-synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	1.9	73
65	High cerebrospinal amyloid-Î² 42 is associated with normal cognition in individuals with brain amyloidosis. <i>EClinicalMedicine</i> , 2021, 38, 100988.	7.1	69
66	Subthalamic nucleusâ€”deep brain stimulation for early motor complications in Parkinson's diseaseâ€”the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	3.9	68
67	Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 65-71.	2.2	68
68	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	2.7	67
69	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 33-42.	1.8	65
70	Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics. <i>Journal of Parkinson's Disease</i> , 2013, 3, 205-214.	2.8	64
71	Cognitive profile of <i>LRRK2</i> -related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	3.9	64
72	Long-term safety and efficacy of levodopaâ€”carbidopa intestinal gel in advanced Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 928-936.	3.9	64

#	ARTICLE	IF	CITATIONS
73	The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies. <i>Movement Disorders</i> , 2017, 32, 310-318.	3.9	63
74	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S53-S56.	2.2	63
75	Post-stroke Movement Disorders: The Clinical, Neuroanatomic, and Demographic Portrait of 284 Published Cases. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2388-2397.	1.6	63
76	Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study. <i>Neurology</i> , 2006, 66, 1941-1943.	1.1	61
77	Diagnostic agreement in patients with psychogenic movement disorders. <i>Movement Disorders</i> , 2012, 27, 548-552.	3.9	60
78	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	9.0	60
79	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.1	58
80	Hallucinations, somaticâ€functional disorders of PDâ€DLB as expressions of thalamic dysfunction. <i>Movement Disorders</i> , 2019, 34, 1100-1111.	3.9	57
81	Parkinsonâ€™s Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	2.8	56
82	Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. <i>Journal of Neurology</i> , 2017, 264, 40-48.	3.6	54
83	Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease. <i>JAMA Network Open</i> , 2019, 2, e187800.	5.9	54
84	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 756-764.	3.9	53
85	Congenital mirror movements. <i>Neurology</i> , 2014, 82, 1999-2002.	1.1	52
86	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. <i>Neurosurgery</i> , 2018, 82, 753-756.	1.1	52
87	Dysfunction in emotion processing underlies functional (psychogenic) dystonia. <i>Movement Disorders</i> , 2018, 33, 136-145.	3.9	51
88	Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 314-320.	1.9	50
89	Consensus for the measurement of the camptocormia angle in the standing patient. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 1-5.	2.2	49
90	Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 426-433.	1.9	49

#	ARTICLE	IF	CITATIONS
91	Parkinsonism and Frontotemporal Dementia: The Clinical Overlap. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 343-349.	2.3	48
92	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	2.8	48
93	Neurologic complications of electrolyte disturbances and acid-base balance. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 365-382.	1.8	47
94	A writing device improves writing in primary writing tremor. <i>Neurology</i> , 2005, 64, 1648-1650.	1.1	45
95	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	2.8	45
96	<i>GBA</i> variants in REM sleep behavior disorder. <i>Neurology</i> , 2020, 95, e1008-e1016.	1.1	45
97	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. <i>PLoS ONE</i> , 2012, 7, e43099.	2.5	44
98	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	3.7	44
99	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	3.9	43
100	Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults. <i>JAMA Neurology</i> , 2020, 77, 461.	9.0	43
101	Clinical Parkinson disease subtyping does not predict pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 189-190.	10.1	42
102	Psychogenic Movement Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1383-1396.	0.8	41
103	Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. <i>European Journal of Neurology</i> , 2020, 27, 975-984.	3.3	41
104	Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: A decision analysis. <i>Movement Disorders</i> , 2010, 25, 1456-1463.	3.9	40
105	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 279-287.	2.8	40
106	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	3.7	40
107	Mirror movements in movement disorders: a review. <i>Tremor and Other Hyperkinetic Movements</i> , 2012, 2, .	2.0	40
108	Advanced therapies in Parkinson's disease: Long-term retrospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 104-108.	2.2	39

#	ARTICLE	IF	CITATIONS
109	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. <i>Movement Disorders</i> , 2016, 31, 1874-1882.	3.9	39
110	Parkinson Disease: An Evolutionary Perspective. <i>Frontiers in Neurology</i> , 2017, 8, 157.	2.4	39
111	Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. <i>Journal of Neurology</i> , 2019, 266, 289-297.	3.6	39
112	Diagnostic Performance of the "Huffing and Puffing" Sign in Functional (Psychogenic) Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 29-32.	1.5	38
113	Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 82-87.	2.2	38
114	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 53-57.	2.2	38
115	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. <i>Movement Disorders</i> , 2007, 22, 328-333.	3.9	37
116	Atypical Motor and Behavioral Presentations of Alzheimer Disease. <i>Neurologist</i> , 2012, 18, 266-272.	0.7	37
117	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	3.1	37
118	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018, 33, 58-61.	3.9	37
119	Tremor retraining as therapeutic strategy in psychogenic (functional) tremor. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 647-650.	2.2	36
120	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	3.9	36
121	Lower-body parkinsonism: reconsidering the threshold for external lumbar drainage. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 50-55.	2.5	35
122	Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 880-887.	3.9	35
123	Long-duration Parkinson's disease: Role of lateralization of motor features. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 77-80.	2.2	34
124	Surgical Treatment of Parkinson Disease. <i>Neurologic Clinics</i> , 2013, 31, 799-808.	1.8	33
125	Hydrocephalic Parkinsonism: lessons from normal pressure hydrocephalus mimics. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 2.	2.2	33
126	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	2.5	33

#	ARTICLE	IF	CITATIONS
127	Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinson's disease data. <i>Npj Digital Medicine</i> , 2019, 2, 95.	10.9	33
128	The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?. <i>Journal of Parkinson's Disease</i> , 2020, 10, S65-S73.	2.8	33
129	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186.	2.8	33
130	Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. <i>Neurology</i> , 2019, 93, e1328-e1338.	1.1	33
131	Advance care planning in Parkinson's disease: ethical challenges and future directions. <i>Npj Parkinson's Disease</i> , 2019, 5, 24.	5.3	32
132	Computer-Guided Deep Brain Stimulation Programming for Parkinson's Disease. <i>Neuromodulation</i> , 2016, 19, 127-132.	0.8	31
133	Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 825-845.	2.8	31
134	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	1.5	31
135	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , 2021, 36, 76-82.	3.9	31
136	Soluble Amyloid- β^2 Consumption in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1403-1415.	2.6	31
137	Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry. <i>Movement Disorders</i> , 2017, 32, 1240-1244.	3.9	30
138	Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. <i>Journal of the Neurological Sciences</i> , 2017, 376, 84-90.	0.6	30
139	Orthostatic hypotension in Parkinson disease: Impact on health care utilization. <i>Parkinsonism and Related Disorders</i> , 2018, 47, 45-49.	2.2	30
140	The Final Nail in the Coffin of Disease Modification for Dopaminergic Therapies. <i>JAMA Neurology</i> , 2019, 76, 747.	9.0	30
141	Head tremor at disease onset: an ataxic phenotype of cervical dystonia. <i>Journal of Neurology</i> , 2019, 266, 1844-1851.	3.6	30
142	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , 2020, 3, 116-132.	4.4	30
143	Postencephalitic parkinsonism and basal ganglia necrosis due to Epstein-Barr virus infection. <i>Neurology</i> , 2011, 76, 1529-1530.	1.1	29
144	Which patients with epilepsy are at risk for psychogenic nonepileptic seizures (PNES)? A multicenter case-control study. <i>Epilepsy and Behavior</i> , 2016, 61, 180-184.	1.7	29

#	ARTICLE	IF	CITATIONS
145	Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 110-112.	2.2	29
146	Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 41-47.	0.9	29
147	Chronic isolated hemifacial spasm as a manifestation of epilepsy partialis continua. <i>Epilepsy and Behavior</i> , 2008, 12, 332-336.	1.7	28
148	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Movement Disorders</i> , 2016, 31, 1049-1054.	3.9	28
149	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	3.9	28
150	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 2.	2.2	27
151	Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus. <i>Movement Disorders</i> , 2020, 35, 1945-1954.	3.9	27
152	Quality of life in isolated dystonia: non-motor manifestations matter. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 622-628.	1.9	27
153	Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 122-127.	2.2	26
154	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	3.6	26
155	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47.	2.2	26
156	Isolated diaphragmatic tremor. <i>Neurology</i> , 2007, 69, 689-692.	1.1	25
157	Teaching Neuro  : Oculomasticatory myorhythmia. <i>Neurology</i> , 2008, 70, e25.	1.1	25
158	The power in numbers: Gut microbiota in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 296-298.	3.9	25
159	Dystonia in atypical parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 25-33.	2.2	25
160	Hemichorea "Hemiballism after Diabetic Ketoacidosis. <i>New England Journal of Medicine</i> , 2010, 363, e27.	27.0	24
161	Functional dystonia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 139, 235-245.	1.8	24
162	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	1.9	24

#	ARTICLE	IF	CITATIONS
163	Anti-N-methyl-D-aspartate Receptor Encephalitis. Archives of Neurology, 2010, 67, 250-1.	4.5	24
164	MOTOR TICS, STEREOTYPIES, AND SELF-FLAGELLATION IN PRIMROSE SYNDROME. Neurology, 2010, 75, 284-286.	1.1	23
165	Our infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease. Movement Disorders, 2016, 31, 597-598.	3.9	23
166	Biometric Digital Health Technology for Measuring Motor Function in Parkinson's Disease: Results from a Feasibility and Patient Satisfaction Study. Frontiers in Neurology, 2017, 8, 273.	2.4	23
167	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	3.7	23
168	Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Annals of Neurology, 2021, 89, 91-98.	5.3	23
169	Petrositis in Ramsay Hunt Syndrome With Multiple Cranial Neuropathies. Archives of Neurology, 2005, 62, 1774.	4.5	22
170	Digital Health Revolution: Is it Time for Affordable Remote Monitoring for Parkinson's Disease?. Frontiers in Neurology, 2015, 6, 34.	2.4	22
171	Peripheral neuropathy as marker of severe Parkinson's disease phenotype. Movement Disorders, 2017, 32, 1256-1258.	3.9	22
172	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). Frontiers in Aging Neuroscience, 2020, 12, 553635.	3.4	22
173	Mirror movements in Parkinson's disease: effect of dopaminergic drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1194-1195.	1.9	21
174	OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review. Movement Disorders Clinical Practice, 2016, 3, 109-115.	1.5	21
175	Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson Disease. Digital Biomarkers, 2018, 1, 126-135.	4.4	21
176	Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology. Frontiers in Neuroscience, 2020, 14, 256.	2.8	21
177	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	3.3	21
178	Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. Journal of the Neurological Sciences, 2006, 246, 149-152.	0.6	20
179	Optimizing extended-release carbidopa/levodopa in Parkinson disease. Neurology: Clinical Practice, 2017, 7, 86-93.	1.6	20
180	Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism and Related Disorders, 2018, 52, 94-97.	2.2	20

#	ARTICLE	IF	CITATIONS
181	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020, 17, 1736-1746.	4.4	20
182	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1<scp>â€Year</scp> Data from the <scp>Openâ€Label BeyoND</scp> Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	3.9	20
183	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. <i>Neurobiology of Aging</i> , 2021, 100, 119.e7-119.e13.	3.1	19
184	Parkinsonism associated with striatal perivascular space dilation. <i>Neurology</i> , 2007, 68, 1540-1540.	1.1	18
185	Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies. <i>Neurologic Clinics</i> , 2010, 28, 913-925.	1.8	18
186	<scp>P</scp>revalence and burden of dysautonomia in advanced Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 796-797.	3.9	18
187	Primrose syndrome: Characterization of the phenotype in 42 patients. <i>Clinical Genetics</i> , 2020, 97, 890-901.	2.0	18
188	Design of a virtual longitudinal observational study in Parkinsonâ€™s disease (ATâ€™HOME PD). <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 308-320.	3.7	18
189	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	3.9	17
190	Dilated Virchowâ€™Robin spaces and parkinsonism. <i>Movement Disorders</i> , 2013, 28, 589-590.	3.9	17
191	Clinical signs in functional (psychogenic) gait disorders: a brief survey. <i>Journal of Clinical Movement Disorders</i> , 2016, 3, 3.	2.2	17
192	<p>Orthostatic hypotension and dementia incidence: links and implications</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	2.2	17
193	The psychogenic toe signs. <i>Neurology</i> , 2011, 77, 508-509.	1.1	16
194	Myoclonus. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1264-1286.	0.8	16
195	Parkinsonismâ€™hyperpyrexia syndrome and deep brain stimulation. <i>Journal of Neurology</i> , 2015, 262, 2780-2782.	3.6	16
196	App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinsonâ€™s Disease: Reliability and Responsiveness. <i>Journal of Parkinson's Disease</i> , 2017, 7, 741-747.	2.8	16
197	Movement disorders in non-encephalopathic Hashimoto's thyroiditis. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 141-142.	2.2	16
198	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. <i>Journal of Neurology</i> , 2021, 268, 3203-3211.	3.6	16

#	ARTICLE	IF	CITATIONS
199	Neural activity in functional movement disorders after inpatient rehabilitation. <i>Psychiatry Research - Neuroimaging</i> , 2020, 303, 111125.	1.8	16
200	Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire. <i>Movement Disorders</i> , 2021, 36, 1392-1400.	3.9	16
201	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 751-753.	1.9	15
202	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-Label ADS-5102. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 183-190.	1.5	15
203	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
204	Should neurologists diagnose and manage functional neurologic disorders? It is complicated. <i>Neurology: Clinical Practice</i> , 2019, 9, 165-167.	1.6	15
205	Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 183-190.	1.5	15
206	Surgical Treatment of Movement Disorders. <i>Clinics in Geriatric Medicine</i> , 2006, 22, 813-825.	2.6	14
207	Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio. <i>Movement Disorders</i> , 2011, 26, 913-914.	3.9	14
208	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.1	14
209	Donanemab in Early Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2021, 385, 666-667.	27.0	14
210	Movement disorders research in 2021: cracking the paradigm. <i>Lancet Neurology</i> , The, 2022, 21, 10-11.	10.2	14
211	Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. <i>Biology</i> , 2022, 11, 535.	2.8	14
212	Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges. <i>Movement Disorders</i> , 2015, 30, 1011-1013.	3.9	13
213	Diagnosing and treating neurogenic orthostatic hypotension in primary care. <i>Postgraduate Medicine</i> , 2015, 127, 702-715.	2.0	13
214	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	1.8	13
215	OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 174-178.	2.2	13
216	Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease. <i>Neurobiology of Aging</i> , 2020, 93, 143.e1-143.e4.	3.1	13

#	ARTICLE	IF	CITATIONS
217	Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based userâ€™s guide. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 23-29.	2.8	12
218	Diagnosis and Treatment of Functional (Psychogenic) Parkinsonism. <i>Seminars in Neurology</i> , 2017, 37, 228-232.	1.4	12
219	Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis. <i>Neurology</i> , 2018, 90, 746-747.	1.1	12
220	The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 295.	9.0	12
221	Atypical absences and recurrent absence status in an adult with Angelman syndrome due to the UBE3A mutation. <i>Epileptic Disorders</i> , 2005, 7, 227-30.	1.3	12
222	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	3.9	11
223	Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the Bedside. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 141-144.	1.5	11
224	The odyssey of complex neurogenetic disorders: From undetermined to positive. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 876-884.	1.6	11
225	Impaired Saccade Adaptation in Tremor-Dominant Cervical Dystoniaâ€™Evidence for Maladaptive Cerebellum. <i>Cerebellum</i> , 2021, 20, 678-686.	2.5	11
226	Uncovering Essential Tremor Genetics: The Promise of Long-Read Sequencing. <i>Frontiers in Neurology</i> , 2022, 13, 821189.	2.4	11
227	Functional movement disorders in neurogeriatric inpatients. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019, 52, 324-329.	1.8	10
228	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021, 7, 16.	5.3	10
229	Functional neurological disorder and somatic symptom disorder in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120017.	0.6	10
230	Movement disorders associated with neuronal antibodies: a data-driven approach. <i>Journal of Neurology</i> , 2022, 269, 3511-3521.	3.6	10
231	A novel <i>DCC</i> mutation and genetic heterogeneity in congenital mirror movements. <i>Neurology</i> , 2011, 77, 1580-1580.	1.1	9
232	Nosography of the â€œessentialâ€• <i>Neurology</i> , 2013, 81, 772-773.	1.1	9
233	Teaching Video Neuro <i>Images</i> : The underrecognized diphasic dyskinesia of Parkinson disease. <i>Neurology</i> , 2017, 89, e83-e84.	1.1	9
234	Parkinson disease in Gaucher disease. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 7.	2.2	9

#	ARTICLE	IF	CITATIONS
235	Future of Neurologic Examination in Clinical Practice. <i>JAMA Neurology</i> , 2018, 75, 383.	9.0	9
236	The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C. <i>Cerebellum and Ataxias</i> , 2019, 6, 9.	1.9	9
237	Movement Disorders in Metabolic Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 7.	4.2	9
238	Teaching Video NeuroImages: Slow periodic myoclonus in subacute sclerosing panencephalitis and fulminant Wilson disease. <i>Neurology</i> , 2019, 93, e1410-e1411.	1.1	9
239	Clinical and Demographic Characteristics of Upper Limb Dystonia. <i>Movement Disorders</i> , 2020, 35, 2086-2090.	3.9	9
240	Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study. <i>Frontiers in Neurology</i> , 2020, 11, 406.	2.4	9
241	How have advances in genetic technology modified movement disorder nosology?. <i>European Journal of Neurology</i> , 2020, 27, 1461-1470.	3.3	9
242	Remote delivery of cognitive behavioral therapy to patients with functional neurological disorders: Promise and challenges. <i>Epilepsy and Behavior Reports</i> , 2021, 16, 100469.	1.0	9
243	Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2021, 11, S117-S122.	2.8	9
244	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	3.9	9
245	Motor excess during movement: Overflow, mirroring, and synkinesis. <i>Clinical Neurophysiology</i> , 2010, 121, 5-6.	1.5	8
246	Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. <i>Neurology</i> , 2016, 86, 1164-1166.	1.1	8
247	Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism. <i>Journal of Clinical Movement Disorders</i> , 2018, 5, 1.	2.2	8
248	Globular Glial Tauopathy May be Mistaken for Corticobasal Syndrome—Pointers for the Clinician. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 439-441.	1.5	8
249	Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome. <i>Cerebellum</i> , 2021, 20, 300-305.	2.5	8
250	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2840-2852.	3.9	8
251	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 159-167.	2.9	8
252	Low soluble amyloid- β 42 is associated with smaller brain volume in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 15-21.	2.2	8

#	ARTICLE	IF	CITATIONS
253	Functional tremor. <i>Journal of the Neurological Sciences</i> , 2022, 435, 120208.	0.6	8
254	Episodic coma in a new leukodystrophy. <i>Pediatric Neurology</i> , 2002, 26, 139-142.	2.1	7
255	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.	1.1	7
256	REVERSIBLE PARKINSONISM AND ATAXIA ASSOCIATED WITH HIGH-DOSE OCTREOTIDE. <i>Neurology</i> , 2008, 70, 2345-2346.	1.1	7
257	Dopamine dysregulation syndrome with psychosis in 24-hour intrastomal levodopa infusion for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 152-154.	2.2	7
258	Teaching Video Neuro Images : Faciobrachial dystonic seizures. <i>Neurology</i> , 2016, 86, e60-1.	1.1	7
259	Movement disorders phenomenology in focal motor seizures. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 161-165.	2.2	7
260	Development and Validation of the Orthostatic Tremor Severity and Disability Scale (OT‐10). <i>Movement Disorders</i> , 2020, 35, 1796-1801.	3.9	7
261	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	4.1	7
262	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. <i>Movement Disorders</i> , 2010, 25, 1520-1523.	3.9	6
263	Writing Orthotic Device for the Management of Writer's Cramp. <i>Frontiers in Neurology</i> , 2013, 4, 2.	2.4	6
264	Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. <i>Movement Disorders</i> , 2017, 32, 476-478.	3.9	6
265	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 402, 81-85.	0.6	6
266	Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 96-102.	2.2	6
267	A rare cervical dystonia mimic in adults: congenital muscular torticollis (fibromatosis colli). <i>Frontiers in Neurology</i> , 2013, 4, 6.	2.4	5
268	Sensory feedback in Parkinson's disease patients with ‐predominant freezing of gait. <i>Frontiers in Neurology</i> , 2013, 4, 14.	2.4	5
269	Cinnamon in a mouse model of PD. <i>Movement Disorders</i> , 2014, 29, 1466-1466.	3.9	5
270	Neuropathic Tremor in Chronic Inflammatory Demyelinating Polyneuropathy: The Acquired Equivalent of the Roussy‐Levy Syndrome. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 173-175.	1.5	5

#	ARTICLE	IF	CITATIONS
271	The Parkinson Care Advocate: Integrating Care Delivery. <i>Frontiers in Neurology</i> , 2017, 8, 364.	2.4	5
272	Internal Versus External Frame of Reference in Functional Movement Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 67-72.	1.8	5
273	Thalamic Deep Brain Stimulation for tremor: The critical role of intraoperative testing. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 45-49.	2.2	5
274	Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension. <i>Journal of Neurology</i> , 2021, 268, 1006-1015.	3.6	5
275	Toward <sc>eâ€Scales</sc>: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
276	A Multiâ€center Genomeâ€wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021, 36, 2795-2801.	3.9	5
277	Arm Levitation as Initial Manifestation of Creutzfeldt-Jakob Disease: CaseÂReport and Review of the Literature. <i>Tremor and Other Hyperkinetic Movements</i> , 2018, 8, 572.	2.0	5
278	What the VaP? The meaning of â€vascular parkinsonismâ€. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 132-134.	2.2	5
279	Cerebellar limb tremor and inferior olivary hypertrophy. <i>Neurology</i> , 2006, 67, 1250-1250.	1.1	4
280	AmÃrico Negrette and Huntington's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 711-713.	0.8	4
281	Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial. <i>Neurology</i> , 2011, 77, e140; author reply e140.	1.1	4
282	Cautionary optimism: caffeine and Parkinsonâ€s disease risk. <i>Journal of Clinical Movement Disorders</i> , 2016, 3, 7.	2.2	4
283	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	2.8	4
284	Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 7-9.	2.2	4
285	Î²â€Blockerâ€Induced Tremor. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 449-452.	1.5	4
286	Of Synuclein and Other Demons. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1391-1393.	2.6	4
287	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	3.9	3
288	Juvenile levodopaâ€responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment. <i>Movement Disorders</i> , 2010, 25, 1860-1867.	3.9	3

#	ARTICLE	IF	CITATIONS
289	The six gaps in the search of neuroprotection for Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 111-113.	2.8	3
290	Placebo effect of medication cost in Parkinson disease: A randomized double-blind study. Neurology, 2015, 85, 742-743.	1.1	3
291	Flamenco dancer posture. Neurology, 2016, 86, 1462-1463.	1.1	3
292	Thalamic deep brain stimulation and gait in orthostatic tremor. Movement Disorders, 2017, 32, 937-938.	3.9	3
293	Teaching Video Neuro Images: Spastic ataxia syndrome. Neurology, 2017, 89, e178-e179.	1.1	3
294	Holmes Tremor-Like Phenotype in DYT1 Dystonia. Movement Disorders Clinical Practice, 2018, 5, 206-208.	1.5	3
295	Perioral and tongue fasciculations in Kennedy's disease. Neurological Sciences, 2018, 39, 777-779.	1.9	3
296	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
297	Progressive Ataxia with Hemiplegic Migraines: a Phenotype of CACNA1A Missense Mutations, Not CAG Repeat Expansions. Cerebellum, 2021, 20, 134-139.	2.5	3
298	Biphasic (Subtherapeutic) Levodopa-Induced Respiratory Dysfunction in Parkinson Disease. Neurology: Clinical Practice, 2021, 11, e402-e406.	1.6	3
299	Recurrence in Pituitary Adenomas in Childhood and Adolescence. Journal of Child Neurology, 2001, 16, 364.	1.4	3
300	Teaching Video Neuro Images: Semiology and localization of ballistic movements. Neurology, 2014, 83, e56-7.	1.1	2
301	Runny nose sign. Neurology: Clinical Practice, 2016, 6, e14-e16.	1.6	2
302	Levodopa and Parkinson Disease "Myths Revisited" Reply. JAMA Neurology, 2017, 74, 1270.	9.0	2
303	Is there even such a thing as "idiopathic normal pressure hydrocephalus"? Annals of Neurology, 2017, 82, 1032-1032.	5.3	2
304	The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S2-S8.	0.9	2
305	Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation. Journal of the Neurological Sciences, 2018, 390, 33-35.	0.6	2
306	Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer". Movement Disorders, 2018, 33, 1028-1029.	3.9	2

#	ARTICLE	IF	CITATIONS
307	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , The, 2020, 19, 643-644.	10.2	2
308	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
309	Teaching NeuroImages: The dentate sign in subacute cerebellar ataxia. <i>Neurology</i> , 2020, 94, e878-e879.	1.1	2
310	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2020, 94, 144-145.	1.1	2
311	Improving anxiety in Parkinson's disease: A cautionary tale about mobile health technologies. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 50-51.	2.2	2
312	Reply to: "The Logic and Pitfalls of Parkinson's as Brain-First Versus Body-First Subtypes" Movement Disorders, 2021, 36, 786-787.	3.9	2
313	Reply to: "Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus" Movement Disorders, 2021, 36, 1043-1044.	3.9	2
314	Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1034-1037.	1.5	2
315	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	3.3	2
316	Timing matters: Otological symptoms and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 23-26.	2.2	2
317	The Phenomenology of Movement Disorders. , 2017, , 29-41.		2
318	Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 56.	2.0	2
319	Vermian Hypoplasia and Arrested Cerebral Myelination in Two Sisters: Variant of Joubert's Syndrome or a New Syndrome?. <i>Journal of Child Neurology</i> , 2003, 18, 755-762.	1.4	1
320	Toxic Movement Disorders: The Approach to the Patient with a Movement Disorder of Toxic Origin. , 2009, , 115-130.		1
321	Amaurotic and ophthalmoplegic presentation of Balint syndrome. <i>Neurology</i> , 2014, 82, 1844-1845.	1.1	1
322	Misleading Imaging and Clinical Features in Pathology-Proven Corticobasal Degeneration. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 315-317.	1.5	1
323	Response to: Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 143.	2.2	1
324	Rhythmical Involuntary Movements (Tremor and Tremor-Like Conditions). , 2016, , 207-263.		1

#	ARTICLE	IF	CITATIONS
325	Abnormalities of Muscle Tone. , 2016, , 49-95.		1
326	Clinical Reasoning: Importance of clinical phenomenology in the era of genetic testing. Neurology, 2018, 90, e534-e537.	1.1	1
327	Teaching Video NeuroImages: The signs of dystonic tremor. Neurology, 2018, 91, e1204-e1205.	1.1	1
328	The "broken wishbone" splenic sign: A diagnostic hallmark for SPG54 spastic ataxia. Journal of the Neurological Sciences, 2019, 403, 114-116.	0.6	1
329	The Pseudodystonia of Paroxysmal Sympathetic Hyperactivity: A Reversible Post-Anoxic Complication. Movement Disorders Clinical Practice, 2020, 7, 987-989.	1.5	1
330	Comment on: "Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information". Parkinsonism and Related Disorders, 2021, 86, 133.	2.2	1
331	Commentary: Atypical, Early-Onset Dystonia in Parkinsonism with Oculogyric Crises and Anterior Horn Cell Disorder due to a Novel <i>DJ-1</i> Mutation. Movement Disorders Clinical Practice, 2021, 8, S19-S20.	1.5	1
332	Recommendations for Virtual Administration of the <i>PSP</i> Rating Scale. Movement Disorders, 2022, 37, 1960-1961.	3.9	1
333	Psychogenic movement disorders. , 0, , 164-174.		0
334	Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for long-term clinical trials. Movement Disorders, 2011, 26, 1371-1371.	3.9	0
335	Commentary for "Opsoclonus myoclonus syndrome associated with GQ1b antibodies". Movement Disorders, 2012, 27, 1616-1617.	3.9	0
336	Commentary for "Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism". Movement Disorders, 2013, 28, 129-130.	3.9	0
337	Ribosomal s15: A novel therapeutic target for Parkinson's disease. Movement Disorders, 2014, 29, 990-990.	3.9	0
338	Effort-Related Behaviors in Charcot's Lectures on Hysteria. Movement Disorders Clinical Practice, 2015, 2, 203-203.	1.5	0
339	Stiff-arm syndrome. Neurology, 2015, 85, 1088-1089.	1.1	0
340	Oral and infusion levodopa therapy in the management of Parkinson's disease. , 0, , 63-75.		0
341	Experimental pharmacological agents in the management of Parkinson's disease. , 0, , 83-92.		0
342	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. , 0, , 249-264.		0

#	ARTICLE	IF	CITATIONS
343	Deep-brain stimulation of the globus pallidus internus in the management of Parkinson's disease. , 0, , 187-194.		0
344	Updated long-term safety from ongoing phase 3 trials of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e97.	2.2	0
345	Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease. , 0, , 195-205.		0
346	Axial Disorders of Movement. , 2016, , 361-435.		0
347	Lack of Organization or Coordination of Voluntary Muscle Activity. , 2016, , 155-205.		0
348	Post-traumatic Functional Mirror Movements in Klippel-Feil Syndrome. Movement Disorders Clinical Practice, 2017, 4, 447-449.	1.5	0
349	Subthalamic or red nucleus? A puzzling question arising during intraoperative recording for DBS. Clinical Neurophysiology, 2017, 128, 558-560.	1.5	0
350	Gaps and controversies in movement disorders: Introduction to the series. Movement Disorders, 2017, 32, 309-309.	3.9	0
351	Q&A with Alberto Espay. Movement Disorders, 2018, 33, 1561-1563.	3.9	0
352	Epileptic chorea: Another window into neural networks?. Journal of the Neurological Sciences, 2018, 394, 138-140.	0.6	0
353	Coxa saltans misdiagnosed as functional gait disorder. Neurology, 2018, 91, 276-277.	1.1	0
354	Is There Vascular Parkinsonism?. Current Clinical Neurology, 2019, , 159-162.	0.2	0
355	Reply to "Neuropathological progression of clinical Parkinson disease subtypes". Nature Reviews Neurology, 2019, 15, 361-362.	10.1	0
356	Cognitive Impairment and Blood Pressure Fluctuations. , 2020, , 122-125.		0
357	Corticobasal: The Syndrome versus the Pathology. , 2020, , 126-128.		0
358	Another Case of Vascular Cognitive Impairment?. , 2020, , 129-132.		0
359	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
360	The Shaky Six and the "Second Reality", 2020, , 1-10.		0

#	ARTICLE	IF	CITATIONS
361	Pieces of a Puzzle?. , 2020, , 11-24.		0
362	Disease "Redefinition" A Tough Pill to Swallow. , 2020, , 25-32.		0
363	Protein Paradox. , 2020, , 41-56.		0
364	The Fault in Our Models. , 2020, , 57-70.		0
365	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
366	Lessons from Oncology. , 2020, , 81-86.		0
367	Our Living Dissonance. , 2020, , 105-110.		0
368	The Scientific and Lay Narratives. , 2020, , 111-124.		0
369	Challenges Viewed from Afar. , 2020, , 125-132.		0
370	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
371	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
372	Note Added at Press Time " Reviving LOF. , 2020, , 150-150.		0
373	Teaching Video NeuroImages: Cluster Breathing in Brainstem-Sparing Bihemispheric Cerebral and Cerebellar Lesions. Neurology, 2021, 96, e2243-e2244.	1.1	0
374	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
375	Patterned or Repetitive Movements and/or Abnormal Posturing. , 2016, , 265-303.		0
376	Movement Disorders in Prionopathies: A Systematic Review. Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	0
377	"Hand mechanogram"™ in epilepsy partialis continua. Practical Neurology, 2021, 21, 543-545.	1.1	0
378	Conditions associated with <sc>ON</sc> "state freezing of gait. Movement Disorders Clinical Practice, 2022, 9, 558-559.	1.5	0